[go: up one dir, main page]

PE20110424A1 - Isoindolonas que inhiben la cinasa mek - Google Patents

Isoindolonas que inhiben la cinasa mek

Info

Publication number
PE20110424A1
PE20110424A1 PE2010001200A PE2010001200A PE20110424A1 PE 20110424 A1 PE20110424 A1 PE 20110424A1 PE 2010001200 A PE2010001200 A PE 2010001200A PE 2010001200 A PE2010001200 A PE 2010001200A PE 20110424 A1 PE20110424 A1 PE 20110424A1
Authority
PE
Peru
Prior art keywords
alkyl
halo
isoindolones
mek kinase
inhibit mek
Prior art date
Application number
PE2010001200A
Other languages
English (en)
Inventor
Emanuela Gancia
Robert Andrew Heald
Philip Jackson
Stephen Price
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41128054&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20110424(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PE20110424A1 publication Critical patent/PE20110424A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035Isoindoles, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

REFERIDA A DERIVADOS DE ISOINDOLONAS DE FORMULA (I), DONDE Z1 ES CR1R1a O NRA; R1 Y R1a SON H, ALQUILO C1-C3, CF3, CHF2, CN O ORA; Z2 ES CR2 O N; R2 ES H, ALQUILO C1-C3, HALO, CF3, ENTRE OTROS; Z3 ES CR3 O N; R3 ES H, HALO, CN, CF3, ENTRE OTROS; R4 ES H, ALQUILO C1-C6, CARBOCICLILO C3-C4; Y ES W-C(O)- O W'; W ES X1-NR5- O R11-O-; R5 ES H O ALQUILO C1-C12; X1 ES R11 O OR11; R11' ES H, ALQUILO C1-C12, ALQUINILO C2-C8, ENTRE OTROS; R11 ES H, ALQUILO C1-C12, ALQUENILO C2-C8, ENTRE OTROS; W' ES Het-R7, -NH-SO2-R8, -NH-SO2-NR8R10; Het ES (a), (b), ENTRE OTROS; X2 ES O, S, ENTRE OTROS; R7 ES H, HALO, CN, CF3, ENTRE OTROS; R8 ES ALQUILO C1-C12, ARILO, ENTRE OTROS; R10 ES H, ALQUILO C1-C6 O CARBOCICLILO C3-C4; R6 ES H, HALO, ALQUILO C1-C6, ALQUENILO C2-C8, ENTRE OTROS; p ES 0, 1, 2 O 3. ES UN COMPUESTO PREFERIDO: (2-HIDROXI-ETOXI)-AMIDA DEL ACIDO 6-(2-FLUORO-4-YODO-FENILAMINO)-1-OXO-2,3-DIHIDRO-1H-ISOINDOL-5-CARBOXILICO. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS INHIBEN LA CINASA MEK Y SON UTILES EN EL TRATAMIENTO DEL CANCER
PE2010001200A 2008-07-01 2009-07-01 Isoindolonas que inhiben la cinasa mek PE20110424A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7743208P 2008-07-01 2008-07-01

Publications (1)

Publication Number Publication Date
PE20110424A1 true PE20110424A1 (es) 2011-07-22

Family

ID=41128054

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2010001200A PE20110424A1 (es) 2008-07-01 2009-07-01 Isoindolonas que inhiben la cinasa mek

Country Status (16)

Country Link
US (1) US8492427B2 (es)
EP (1) EP2307364B1 (es)
JP (1) JP5615274B2 (es)
KR (1) KR20110028376A (es)
CN (1) CN102137843A (es)
AU (1) AU2009266953A1 (es)
BR (1) BRPI0910200A2 (es)
CA (1) CA2727252A1 (es)
CL (1) CL2010001637A1 (es)
ES (1) ES2426096T3 (es)
IL (1) IL209892A0 (es)
MX (1) MX2010014565A (es)
PE (1) PE20110424A1 (es)
RU (1) RU2495028C2 (es)
WO (1) WO2010003022A1 (es)
ZA (1) ZA201008962B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012018638A2 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures
EP2598661B1 (en) 2010-07-26 2017-09-27 Biomatrica, INC. Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
CN102020651B (zh) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-芳基氨基吡啶酮甲酰胺mek抑制剂
AU2013337702A1 (en) 2012-11-02 2015-05-21 Merck Patent Gmbh Method of reducing adverse effects in a cancer patient undergoing treatment with a MEK inhibitor
EP3249054A1 (en) 2012-12-20 2017-11-29 Biomatrica, INC. Formulations and methods for stabilizing pcr reagents
EP3007556B1 (en) 2013-06-13 2020-05-20 Biomatrica, INC. Cell stabilization
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
WO2015058589A1 (zh) * 2013-10-25 2015-04-30 上海恒瑞医药有限公司 吡啶酮类衍生物、其制备方法及其在医药上的应用
KR102408261B1 (ko) 2014-02-03 2022-06-10 비타이 파마슈티컬즈, 엘엘씨 Ror-감마의 디하이드로피롤로피리딘 저해제
CN103922992B (zh) * 2014-04-25 2015-09-02 温州大学 一种抗癌活性吲哚酮衍生物、合成方法及其用途
EP3942931A1 (en) 2014-06-10 2022-01-26 Biomatrica, INC. Stabilization of thrombocytes at ambient temperatures
US20170114323A1 (en) 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
DK3207043T6 (da) 2014-10-14 2020-01-20 Vitae Pharmaceuticals Llc Dihydropyrrolopyridin-inhibitorer af ror-gamma
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
CN104860869B (zh) * 2015-04-03 2017-11-03 北京大学 具有mek激酶抑制功能的化合物及其制备方法与应用
EP3300500B9 (en) 2015-05-20 2021-01-13 Amgen Inc. Triazole agonists of the apj receptor
US10301261B2 (en) 2015-08-05 2019-05-28 Vitae Pharmaceuticals, Llc Substituted indoles as modulators of ROR-gamma
WO2017033113A1 (en) 2015-08-21 2017-03-02 Acerta Pharma B.V. Therapeutic combinations of a mek inhibitor and a btk inhibitor
EP3868750A1 (en) 2015-11-20 2021-08-25 Vitae Pharmaceuticals, LLC Modulators of ror-gamma
KR20250047404A (ko) 2015-12-08 2025-04-03 바이오매트리카 인코포레이티드 적혈구 침강 속도의 감소
TWI757266B (zh) 2016-01-29 2022-03-11 美商維它藥物有限責任公司 ROR-γ調節劑
MX2018012471A (es) 2016-04-15 2019-02-21 Genentech Inc Metodos de diagnostico y terapeuticos para el cancer.
WO2017192485A1 (en) 2016-05-03 2017-11-09 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
EP3541810B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
US11046680B1 (en) 2016-11-16 2021-06-29 Amgen Inc. Heteroaryl-substituted triazoles as APJ receptor agonists
US10689367B2 (en) 2016-11-16 2020-06-23 Amgen Inc. Triazole pyridyl compounds as agonists of the APJ receptor
WO2018097944A1 (en) 2016-11-16 2018-05-31 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
WO2018093577A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the apj receptor
EP3541802B1 (en) 2016-11-16 2025-01-01 Amgen Inc. Alkyl substituted triazole compounds as agonists of the apj receptor
TWI801394B (zh) 2017-06-23 2023-05-11 大陸商基石藥業(蘇州)有限公司 作為mek抑制劑的類香豆素環類化合物及其應用
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
CN111225914B (zh) 2017-07-24 2022-10-11 生命医药有限责任公司 RORγ的抑制剂
TW202428305A (zh) 2017-09-08 2024-07-16 美商建南德克公司 癌症之診斷及治療方法
US11149040B2 (en) 2017-11-03 2021-10-19 Amgen Inc. Fused triazole agonists of the APJ receptor
CN111801314B (zh) 2018-01-02 2023-10-31 西尔洛克治疗公司 Ask1抑制剂化合物及其用途
US20210008047A1 (en) 2018-02-13 2021-01-14 Vib Vzw Targeting minimal residual disease in cancer with rxr antagonists
WO2019213006A1 (en) 2018-05-01 2019-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells
WO2022251193A1 (en) 2021-05-27 2022-12-01 Mirati Therapeutics, Inc. Combination therapies
WO2024033381A1 (en) 2022-08-10 2024-02-15 Vib Vzw Inhibition of tcf4/itf2 in the treatment of cancer

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA711710B (en) 1970-05-28 1971-12-29 Squibb & Sons Inc Amino derivatives of purazolo-pyridine carboxylic acids and esters
US3736326A (en) * 1971-03-29 1973-05-29 Squibb & Sons Inc Isoxazolopyridine carboxylic acids and esters
US4012373A (en) * 1972-09-22 1977-03-15 E. R. Squibb & Sons, Inc. Pyrazolo[3',4'-2,3]pyrido[4,5-e]b-benzo-1,5-diazepinones
GB8404586D0 (en) * 1984-02-22 1984-03-28 Beecham Group Plc Compounds
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
CN1358094A (zh) 1999-07-16 2002-07-10 沃尼尔·朗伯公司 用mek抑制剂治疗慢性疼痛的方法
JP2002020386A (ja) 2000-07-07 2002-01-23 Ono Pharmaceut Co Ltd ピラゾロピリジン誘導体
IL153817A0 (en) 2000-07-19 2003-07-31 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
CA2478534A1 (en) 2002-03-13 2003-09-25 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as mek inhibitors
CA2478374C (en) * 2002-03-13 2009-01-06 Eli M. Wallace N3 alkylated benzimidazole derivatives as mek inhibitors
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
GB0316232D0 (en) 2003-07-11 2003-08-13 Astrazeneca Ab Therapeutic agents
GB0316237D0 (en) 2003-07-11 2003-08-13 Astrazeneca Ab Therapeutic agents
US20050049276A1 (en) * 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
WO2005009975A2 (en) * 2003-07-24 2005-02-03 Warner-Lambert Company Llc Benzimidazole derivatives as mek inhibitors
DK1663242T3 (da) 2003-08-07 2011-08-01 Rigel Pharmaceuticals Inc 2,4-Pyrimidindiamin-forbindelser og anvendelse som antiproliferative midler
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7538120B2 (en) * 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
JP4869075B2 (ja) * 2003-11-19 2012-02-01 アレイ バイオファーマ、インコーポレイテッド Mekの複素環阻害剤及びその使用方法
DE602004011985T2 (de) 2003-11-25 2009-03-05 Eli Lilly And Co., Indianapolis Modulatoren des peroxisomproliferatoraktivierten rezeptors
EP1694663A1 (en) 2003-12-19 2006-08-30 Biovitrum Aktiebolag Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-ht6 receptor-related disorder
ATE381554T1 (de) 2003-12-22 2008-01-15 Basilea Pharmaceutica Ag Aroylfurane und aroylthiophene, die sich für die behandlung von krebs eignen
EP1699488A2 (en) 2003-12-23 2006-09-13 Pfizer Products Incorporated Therapeutic combination for cognition enhancement and psychotic disorders
WO2007027855A2 (en) 2005-09-01 2007-03-08 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
EP1934174B1 (en) 2005-10-07 2011-04-06 Exelixis, Inc. Azetidines as mek inhibitors for the treatment of proliferative diseases
WO2008028141A2 (en) 2006-08-31 2008-03-06 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof

Also Published As

Publication number Publication date
CN102137843A (zh) 2011-07-27
AU2009266953A2 (en) 2011-01-27
EP2307364A1 (en) 2011-04-13
KR20110028376A (ko) 2011-03-17
JP2011526924A (ja) 2011-10-20
WO2010003022A8 (en) 2010-09-30
CA2727252A1 (en) 2010-01-07
IL209892A0 (en) 2011-02-28
WO2010003022A1 (en) 2010-01-07
US8492427B2 (en) 2013-07-23
RU2011103434A (ru) 2012-08-10
BRPI0910200A2 (pt) 2015-09-29
US20110124622A1 (en) 2011-05-26
CL2010001637A1 (es) 2011-07-15
RU2495028C2 (ru) 2013-10-10
EP2307364B1 (en) 2013-06-19
AU2009266953A1 (en) 2010-01-07
MX2010014565A (es) 2011-03-04
JP5615274B2 (ja) 2014-10-29
ES2426096T3 (es) 2013-10-21
ZA201008962B (en) 2012-03-28

Similar Documents

Publication Publication Date Title
PE20110424A1 (es) Isoindolonas que inhiben la cinasa mek
ES2528797T3 (es) Compuestos de aza-benzotiofenilo y métodos de uso
PE20081354A1 (es) Compuestos de azaindolilo como inhibidores de mek
PE20091158A1 (es) 5-anilinoimidazopiridinas y metodos de uso
PE20081630A1 (es) Quinazolinas para la inhibicion de pdk1
PE20121048A1 (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
CL2012000311A1 (es) Compuestos derivados que contiene ciclos con 3 atomos de nitrogeno; utiles en el tratamiento de parasitosis en animales.
PE20081174A1 (es) Inhibidores de metaloproteasas derivados de heterociclos
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
EA200800182A1 (ru) Циклические анилинопиридинотриазины в качестве ингибиторов gsk-3
PE20140609A1 (es) Diazacarbazoles y metodos de uso
PE20081353A1 (es) Compuestos del inhibidor de fosfoinositida 3-cinasa
MA38540B1 (fr) Dérivés de naphtyridine utiles comme antagonistes de l'intégrine alpha-v-bêta-6
GEP201706728B (en) Noxious organism control agent
MX2019010772A (es) Compuestos heterociclicos utiles como inhibidores dobles de autotaxina (atx)/anhidrasa carbonica (ca).
EA201100037A1 (ru) Органические соединения
PE20120690A1 (es) Derivados de 5-fluoropirimidinona
AR084011A1 (es) Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen
CO6382123A2 (es) Antagonistas de la via hedgehog de ftalazina disustituida
EA201491535A1 (ru) Гербицидно-эффективные сульфиниламинобензамиды
CY1115247T1 (el) Ενωσεις συμπυκνωμενων δακτυλιων και χρηση αυτων
UA117922C2 (uk) Насичені азотовмісні та n-ациловані гетероцикли, що посилюють дію активного антибіотика проти мікобактерій
MX2010007543A (es) Inhibidores de iap.
PE20120917A1 (es) Derivados de pirazoles y su preparacion
EA201170828A1 (ru) Конденсированные гетероциклические производные оксадиазола, подходящие для лечения рассеянного склероза

Legal Events

Date Code Title Description
FA Abandonment or withdrawal